Up next

Autoplay

Dr. Andrew Brohl at ASCO 2023: Abstract No. 9534

2 Views • 07/17/23
Share
Embed
administrator
administrator
Subscribers
0

At ASCO 2023, Moffitt's Dr. Andrew Brohl discusses a phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay